Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ossenkoppele, Gert J  [Clear All Filters]
2013
Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, et al. Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells. PLoS One. 2013;8(11):e78897.
2014
Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, et al. Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS One. 2014;9(9):e107587.
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
2018
Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui M-L, Klootwijk LLE de Vos, et al. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. Cell Rep. 2018;25(11):3021-3035.e5.
2019
Moshaver B, Wouters RF, Kelder A, Ossenkoppele GJ, Westra GAH, Kwidama Z, Rutten AR, Kaspers GJL, Zweegman S, Cloos J, et al. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. Leuk Res. 2019;81:27-34.
de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, Hazenberg MD. Survival of early post-hematopoietic stem cell transplantation relapse of myeloid malignancies. Eur J Haematol. 2019.
2020
Hanekamp D, Ngai LLam, Janssen JJwm, van de Loosdrecht AA, Ossenkoppele GJ, Cloos J. Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells. Blood. 2020.
Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, et al. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5(1).
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang J-H, Porkka K, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020;383(26):2526-2537.
2022
de Leeuw DC, Ossenkoppele GJ, Janssen JJWM. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment. Curr Oncol Rep. 2022.
2023
Ngai LLam, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, van Marsbergen LOudshoorn-, Scholten WJ, Snel AN, et al. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood. 2023.